众生药业：公司核心中成药产品均已完成或正推进说明书中安全性内容的修订工作，符合相关的要求

Group 1 - The company is closely monitoring regulatory policy adjustments in the traditional Chinese medicine (TCM) industry and is committed to adhering to national drug regulatory requirements in its production, operations, and product development [2] - The core TCM products of the company have either completed or are in the process of revising the safety content in their instructions to comply with relevant requirements [2] - The company is addressing investor concerns regarding compliance rectification timelines and resource planning for its TCM product line, indicating a proactive approach to potential risks [2]